UniQure Plans Q3 Submission for Huntington's Gene Therapy After FDA Reversal

FDA Reverses Stance, Accepts UniQure's Huntington's Gene Therapy Filing

The FDA has reversed its previous stance, now agreeing to accept uniQure's regulatory filing for its Huntington’s disease gene therapy, AMT-130, based on three-year data from its Phase 1/2 trial. This decision, expected in the third quarter, signals a more flexible regulatory environment under acting commissioner Kyle Diamantas, contrasting with the agency's earlier refusal. Several other biotech companies, including Disc Medicine, Sanofi, and Replimune, have also reported more favorable interactions with the FDA recently. However, the press release raises questions about the long-term consistency of this approach, given the temporary nature of the acting commissioner's role and past instances of FDA reversals.

• The FDA has made a significant U-turn, agreeing to accept uniQure's regulatory filing for its Huntington's disease gene therapy, AMT-130. This decision is based on three-year data from the company's Phase 1/2 trial, a submission the agency had previously refused late last year. This reversal is a crucial development for uniQure, paving the way for a planned third-quarter submission and potentially accelerating the path to market for this rare disease treatment.
• UniQure's positive regulatory news is indicative of a broader shift in the FDA's approach under acting commissioner Kyle Diamantas. The agency appears to be operating in a 'caretaker mode,' demonstrating increased flexibility on regulatory paths for applications where concerns were previously raised. This trend has also benefited other companies like Disc Medicine, Sanofi, and Replimune, who have reported more collaborative dialogue and favorable decisions from the FDA.
• Despite the current positive regulatory climate, the press release highlights concerns about the long-term predictability of FDA decisions. Acting Commissioner Diamantas's tenure is legally limited to 210 days under the Federal Vacancies Reform Act, raising questions about whether a future permanent commissioner might reverse these more flexible stances. This uncertainty poses a challenge for biotech companies making critical business decisions based on current regulatory guidance.

Addressing Key Challenges in Huntington's Disease Treatment

Current treatment approaches for Huntington's disease (HD) remain strictly symptomatic, with no approved disease-modifying or disease-slowing therapy available to date. The therapeutic landscape is further complicated by incomplete understanding of huntingtin protein function, the multifactorial pathogenic mechanisms underlying HD, and the lack of validated biomarkers to track functional decline or measure therapeutic efficacy. Several promising modalities are advancing through clinical development, but significant translational hurdles persist across pharmacological, cellular, and surgical strategies.

• Absence of disease-modifying treatment: No therapy currently exists that delays HD onset, slows progression, or halts neurodegeneration. Treatment remains directed at reducing symptom severity — particularly chorea, the most common motor manifestation — rather than addressing underlying disease biology. Riluzole (50 mg twice daily for 3 years) demonstrated no neuroprotective or symptomatic benefit in a randomized, double-blind trial of 537 patients (p = 0.93, Mann-Whitney U test).

• Biomarker gap: A fundamental barrier to therapeutic development is the absence of reliable biomarkers with sufficient sensitivity and specificity to track functional decline over time or to serve as endpoints for interventional trials.

• Incomplete mechanistic understanding: Despite identification of the HD gene, the normal function of the huntingtin protein remains unknown. HD is increasingly recognized as emerging from multiple pathogenic processes, including somatic instability of the mutant HTT CAG repeat tract, which drives diverse downstream deleterious consequences and complicates target selection.

• HTT-lowering strategy optimization: Multiple HTT-lowering modalities — including antisense oligonucleotides (ASOs) and siRNAs — have entered clinical trials, targeting either both HTT and HTT1a together or full-length HTT alone. However, the optimal targeting strategy remains under active investigation. An intrathecally delivered ASO aimed at lowering huntingtin is currently in its first human clinical trial, with additional ASOs expected to enter trials within 1–2 years.

• Diagnostic complexity: Diagnosis can be clinically challenging, particularly when a patient with chronic neurological disease presents with acute deterioration. Cognitive impairment prominent in HD, combined with phenotypic overlap with other conditions (e.g., hypercalcaemia), can result in diagnostic delay and prolonged hospital admission.

• Limitations of cellular and gene therapies: Fetal neural transplantation has shown unsatisfactory efficacy in both preclinical and clinical investigations. Stem cell-based therapies (SCT) have entered early clinical trials, with results not expected for several years; long-term efficacy and side effects of gene therapy modalities have yet to be verified, and cell-based therapy models face numerous translational challenges.

• Neurosurgical intervention requirements: Experimental approaches — including deep brain stimulation, neurotrophic factor delivery, cell transplantation, RNA interference, ASO delivery, and intrabody administration — require direct neurosurgical implantation or intracranial delivery due to the inability of these agents to cross the blood-brain barrier via oral or intravenous routes. Efficacy in HD patients remains to be established for all of these strategies.

• Rehabilitation evidence gap: Few studies exist and no clinical guidelines have been established for rehabilitation in HD, representing a significant unmet need in the comprehensive management of affected patients.

How FDA's Evolving Stance Shapes the HD Treatment Landscape

The Huntington's disease (HD) treatment landscape over the past five years has been defined as much by high-profile setbacks as by emerging scientific directions. Most notably, antisense oligonucleotide (ASO) candidates — which had represented the leading disease-modifying strategy — experienced significant clinical trial failures, underscoring the limitations of early HTT-lowering approaches and catalyzing a broader reassessment of therapeutic strategy. Current gene therapy programs continue to pursue RNA-targeted HTT knockdown via splice modulation, siRNA, and ASOs, though a key recognized limitation is that these approaches do not adequately account for the diversity of HTT transcript isoforms under normal physiological conditions and in disease states. Nucleic acid therapeutics designed to silence the causative gene in polyglutamine diseases have advanced into clinical evaluation, yet as of 2026, none have received regulatory approval. A notable preclinical advance includes an acyclic serinol nucleic acid (SNA)-modified siRNA targeting CAG repeats, which demonstrated selective allele-specific silencing of polyglutamine-encoding sequences without disrupting wild-type counterparts following intracerebroventricular administration in mouse models.

Beyond gene-silencing strategies, the field is actively exploring complementary modalities. Cell replacement therapies — encompassing fetal neural tissue transplantation and more recent alternative cell source approaches — have been investigated in both animal models and HD patients, with stem cells demonstrating capacity to generate the desired striatal neuron phenotype and deliver neuroprotective growth factors to degenerating host tissue. CRISPR/Cas9 and RNA interference approaches have similarly been studied in animal models and human-derived cells. On the small-molecule front, a novel in-silico fragment scanning approach identified GLYN122, a preclinical candidate that directly binds and reduces mutant huntingtin (mHTT), induces neuronal autophagy, and reduced mHTT in the cortex and striatum of the R6/2 mouse model while improving motor symptoms. Separately, a randomized crossover trial of dextromethorphan/quinidine (20/10 mg) for HD-associated irritability enrolled 20 participants but found no statistically significant advantage over placebo across irritability, motor, behavioral, or cognitive endpoints — reflecting the absence of any FDA-approved agent specifically targeting HD neuropsychiatric symptoms.

The infrastructure supporting HD clinical research has grown substantially in parallel with these scientific efforts. Enroll-HD, established in 2012, now operates across 159 clinical sites in 21 countries on four continents and has recruited nearly 25,000 participants, generating a large longitudinal clinical database with associated biosamples that accelerates mechanistic research and facilitates enrollment in interventional trials. Polymorphic variation in the ADORA2A gene — which influences age at HD onset — has identified adenosine system modulation as a potential novel therapeutic avenue. Despite this broad pipeline activity, no disease-modifying therapy has yet been approved, and the fundamental challenge of halting or reversing HD progression remains unresolved. Based on the volume of planned, ongoing, and completed gene therapy trials across rare CNS genetic diseases, regulatory approvals in adjacent areas are anticipated in the near term, which may inform accelerated development pathways for HD.

The Pipeline for Unapproved Huntington's Disease Therapies

The investigational pipeline for Huntington's disease encompasses a broad spectrum of mechanistic approaches, reflecting the disease's complex pathophysiology involving transcriptional dysregulation, excitotoxicity, and neuroinflammation. Across the literature, three mechanistic categories consistently emerge as dominant in unapproved, trial-stage therapeutics.

• Huntingtin (HTT) lowering and protein homeostasis modulation represents the most extensively pursued disease-modifying strategy, appearing across multiple publications from 2019 through 2024. Approaches include antisense oligonucleotides (ASOs) targeting the HTT gene — including HTT ASOs delivered via apolipoprotein A-I nanodisks (apoA-I NDs) — as well as small molecules aimed at reducing mutant huntingtin expression. These agents have demonstrated mutant HTT lowering in striatum, cortex, liver, skeletal muscle, and heart in preclinical BACHD mouse models, with clinical translation ongoing.

• Modulation of neuroinflammation is a recurrently cited mechanism spanning 2019 to 2024 publications, with strategies targeting both pro- and anti-inflammatory signaling pathways implicated in neurodegeneration. Laquinimod, an aryl hydrocarbon receptor (AHR) agonist, has entered clinical trials for HD via this pathway. Additionally, agents targeting the kynurenine pathway — including kynurenine monooxygenase (KMO) inhibitors and kynurenic acid/quinolinic acid modulators — have shown significant improvement in animal models and represent an active area of clinical investigation.

• Neuroprotection and antiapoptotic/cell death inhibition constitutes the third major mechanistic cluster, encompassing HDAC inhibition (notably class IIa HDAC4 inhibition via diarylcyclopropane hydroxamic acids), glutamate antagonism (e.g., memantine's uncompetitive NMDAR antagonism and riluzole's glutamatergic properties), and mitochondrial function modulation. Compounds such as minocycline and cysteamine, which demonstrated benefits in HD models, have also advanced to clinical trials under this broader neuroprotective rationale. Despite preclinical success across this category, efficacy in phase I and II trials remains to be conclusively established.

A New Regulatory Horizon for Huntington's Gene Therapy

The FDA's recent decision to accept uniQure's regulatory filing for its Huntington's disease (HD) gene therapy, AMT-130, based on Phase 1/2 data, marks a significant moment for the neurodegenerative disease community. This move, particularly after an earlier refusal, suggests a potentially more flexible regulatory environment, which could be a game-changer for conditions like HD, where drug development has historically faced immense challenges and a very low success rate.

Huntington's disease is a devastating, inherited neurodegenerative disorder characterized by progressive neuronal loss, for which current treatments primarily manage symptoms rather than altering the disease course. The promise of gene therapy, especially using adeno-associated virus (AAV) vectors, has been a beacon of hope for such conditions, yet its full potential in HD has remained largely underexplored. The FDA's willingness to consider earlier-stage data for filing could accelerate the path to market for novel, potentially disease-modifying therapies, offering a new paradigm for patients with limited options.

However, this optimism must be tempered with a realistic view of the inherent risks. While Phase 1/2 data can be promising, the long-term efficacy and safety of gene therapies in complex neurological disorders still require rigorous evaluation in larger, later-stage trials. Concerns about potential immune responses or other adverse events associated with gene delivery remain paramount. Furthermore, the regulatory landscape itself presents a degree of uncertainty; the event summary highlights questions about the consistency of this flexible approach, given the temporary nature of the acting commissioner's role and the FDA's history of reversals. This raises the risk of future shifts in regulatory stance that could impact subsequent approvals or post-market requirements.

From a commercial perspective, new-to-market neurologic medications often come with substantial costs, leading to high out-of-pocket expenses for patients and potentially low utilization despite approval. This suggests that even with a favorable regulatory path, market access and reimbursement challenges for a high-cost gene therapy like AMT-130 will be critical considerations. Ultimately, this development could invigorate research and investment in gene therapies for other neurodegenerative diseases, but careful navigation of clinical, regulatory, and commercial hurdles will be essential for realizing its full potential.